GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
Abstract Background Acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation accounts for a large proportion of AML patients and diagnosed with poor prognosis. Although the prognosis of FLT3-ITD AML has been greatly improved, the drug resistance fr...
Main Authors: | Xinhua Xiao, Peihong Wang, Weina Zhang, Jiayi Wang, Mansi Cai, Hua Jiang, Yingli Wu, Huizhuang Shan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-023-03142-y |
Similar Items
-
Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01) -
Frequency of FLT3/ITD Mutation in Patients with Acute Myeloid Leukaemia presenting at Combined Military Hospital, Rawalpindi
by: Anil Babar, et al.
Published: (2023-12-01) -
Comparison of fragment analysis and PCR electrophoresis methods for the detection of FLT3‑ITD mutations in patients with acute myeloid leukemia
by: I. E. Maslyukova, et al.
Published: (2022-11-01) -
Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01) -
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
by: Andrew Y. Li, et al.
Published: (2021-03-01)